Industry Strength Score
34/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ARGENX SE (1AE.DE) Stock Price & Overview
FRA:1AE • NL0010832176
Current stock price
655.8 EUR
-9.4 (-1.41%)
Last:
The current stock price of 1AE.DE is 655.8 EUR. Today 1AE.DE is down by -1.41%. In the past month the price increased by 7.09%.
1AE.DE Key Statistics
1-Month Range619.6 - 720.2
Current 1AE.DE stock price positioned within its 1-month range.
- Market Cap
- 40.784B
- P/E
- 39.32
- Fwd P/E
- 28.29
- EPS (TTM)
- 16.68
- Dividend Yield
- N/A
1AE.DE Stock Performance
Today
-1.41%
1 Week
-3.25%
1 Month
+7.09%
3 Months
-6.77%
Longer-term
6 Months -6.98%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
1AE.DE Stock Chart
1AE.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1AE.DE.
Chartmill TA Rating
Chartmill Setup Rating
1AE.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to 1AE.DE. While 1AE.DE has a great health rating, its profitability is only average at the moment.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
1AE.DE Earnings
On February 26, 2026 1AE.DE reported an EPS of 8.02 and a revenue of 1.32B. The company beat EPS expectations (28.35% surprise) and beat revenue expectations (0.3% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$8.02
Revenue Reported1.322B
EPS Surprise 28.35%
Revenue Surprise 0.30%
1AE.DE Forecast & Estimates
25 analysts have analysed 1AE.DE and the average price target is 896.61 EUR. This implies a price increase of 36.72% is expected in the next year compared to the current price of 655.8.
For the next year, analysts expect an EPS growth of 39.01% and a revenue growth 42.02% for 1AE.DE
Analysts
Analysts84.8
Price Target896.61 (36.72%)
EPS Next Y39.01%
Revenue Next Year42.02%
1AE.DE Financial Highlights
Over the last trailing twelve months 1AE.DE reported a non-GAAP Earnings per Share(EPS) of 16.68. The EPS increased by 1028.32% compared to the year before.
Income Statements
Revenue(TTM)7.02B
Net Income(TTM)2.05B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.23% | ||
| ROA | 23.62% | ||
| ROE | 28.01% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%762.37%
Sales Q2Q%79.03%
EPS 1Y (TTM)1028.32%
Revenue 1Y (TTM)220.39%
1AE.DE Ownership
Ownership
Inst Owners45.26%
Shares62.19M
Float62.17M
Ins Owners0.12%
Short Float %N/A
Short RatioN/A
1AE.DE Industry Overview
1AE.DE operates in the Biotechnology sub-industry within the Health Care sector. This group contains 52 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
78/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
19%
Outperformed 19% of sub-industries
3 Month Rank
20%
Outperformed 20% of sub-industries
6 Month Rank
35%
Outperformed 35% of sub-industries
Industry Fundamentals & Breadth
- Members
- 52
- New Highs
- 1.9%
- New Lows
- 11.5%
- Average ROE
- 26.7%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 25.9%
- Average P/E
- 38.2
- Average Fwd P/E
- 30.2
- Average Debt/Equity
- 0.0
1AE.DE Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.82 | 40.797B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.748B | ||
| ABVX | ABIVAX SA | N/A | 7.414B | ||
| 2X1 | ABIVAX SA | N/A | 7.402B | ||
| GXE | GALAPAGOS NV | N/A | 1.583B | ||
| GLPG | GALAPAGOS NV | N/A | 1.58B | ||
| NANO | NANOBIOTIX | N/A | 1.367B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1B | ||
| PHARM | PHARMING GROUP NV | 47.15 | 997.578M | ||
| PHGN | PHARMING GROUP NV | 46.42 | 992.281M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 873.421M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1AE.DE
Company Profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Company Info
IPO: 2014-07-10
ARGENX SE
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND NL
Employees: 1863
Phone: 31763030
ARGENX SE / 1AE.DE FAQ
What does ARGENX SE do?
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
What is the stock price of ARGENX SE today?
The current stock price of 1AE.DE is 655.8 EUR. The price decreased by -1.41% in the last trading session.
What is the dividend status of ARGENX SE?
1AE.DE does not pay a dividend.
What is the ChartMill rating of ARGENX SE stock?
1AE.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for 1AE.DE stock?
25 analysts have analysed 1AE.DE and the average price target is 896.61 EUR. This implies a price increase of 36.72% is expected in the next year compared to the current price of 655.8.
How is the valuation of ARGENX SE (1AE.DE) based on its PE ratio?
The PE ratio for ARGENX SE (1AE.DE) is 39.32. This is based on the reported non-GAAP earnings per share of 16.68 and the current share price of 655.8 EUR.
When does ARGENX SE (1AE.DE) report earnings?
ARGENX SE (1AE.DE) will report earnings on 2026-05-07.